TRADING UPDATES: Avacta appoints "seasoned" new deputy chair
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News: Read More
| Price | 78.50p on 18-09-2026 at 09:08:02 |
|---|---|
| Change | 2.50p 3.29% |
| Buy | 80.00p |
| Sell | 77.00p |
| Last Trade: | Sell 5,945.00 at 77.4555p |
| Day's Volume: | 670,166 |
| Last Close: | 76.00p |
| Open: | 75.50p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 75.50p - 79.00p |
| 52wk Range: | 49.00p - 90.50p |
| Market Capitalisation: | £367.81m |
| VWAP: | 77.77753p |
| Shares in Issue: | 468.55m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 5,945 | 77.4555p | Ordinary |
10:08:00 - 18-Sep-26 |
| Sell* | 1 | 77.00p | Ordinary |
10:03:44 - 18-Sep-26 |
| Buy* | 2,544 | 78.6141p | Ordinary |
10:02:36 - 18-Sep-26 |
| Buy* | 1,984 | 78.618p | Ordinary |
10:00:13 - 18-Sep-26 |
| Sell* | 325 | 77.10p | Ordinary |
09:59:54 - 18-Sep-26 |
| Buy* | 9,500 | 78.647p | Ordinary |
09:35:10 - 18-Sep-26 |
| Sell* | 7,311 | 77.366p | Ordinary |
09:33:00 - 18-Sep-26 |
| Buy* | 540 | 80.00p | SI Trade |
09:29:30 - 18-Sep-26 |
| Sell* | 8,350 | 78.00p | Ordinary |
09:29:28 - 18-Sep-26 |
| Sell* | 129 | 78.00p | Ordinary |
09:26:50 - 18-Sep-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 16th Sep 2026 7:00 am | RNS | Clinical Proof of Mechanism for preCISION Platform |
| 14th Sep 2026 7:00 am | RNS | Mats Blom to Board as Chair of Audit Committee |
| 4th Sep 2026 7:00 am | RNS | Accelerated Payment Convertible Bond Installment |
| 1st Sep 2026 7:00 am | RNS | Share Option Awards to Management Team at Avacta |
| 9th Jul 2026 7:00 am | RNS | Accelerated Amortized Payment of Bond Installment |
| 8th Jul 2026 7:00 am | RNS | Avacta Appoints Patrick Vink Deputy Chairman |
| 25th Jun 2026 7:00 am | RNS | Platform-Validating Data with Faridoxorubicin |
| 25th Jun 2026 7:00 am | RNS | FDA Agreement on Pivotal Trial Design for AVA6000 |
| 23rd Jun 2026 7:00 am | RNS | Result of AGM |
| 22nd Jun 2026 7:00 am | RNS | Year-to-date business update ahead of AGM |